Blood Cancer Talks Podcast Por Rajshekhar Chakraborty Ashwin Kishtagari and Edward Cliff arte de portada

Blood Cancer Talks

Blood Cancer Talks

De: Rajshekhar Chakraborty Ashwin Kishtagari and Edward Cliff
Escúchala gratis

Acerca de esta escucha

 This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk© 2025 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Episode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera Mohan

    Episode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera Mohan
    Jul 9 2025

    In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan.
    https://pubmed.ncbi.nlm.nih.gov/39841461/
    https://pubmed.ncbi.nlm.nih.gov/40459097/
    Más Menos
    25 m
  • Episode 61. Menin Inhibitors in AML with Dr. Eytan Stein

    Episode 61. Menin Inhibitors in AML with Dr. Eytan Stein
    Jun 24 2025

    In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed:

    • ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022
    • Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6
    • DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79
    • AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826
    • Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutated
    • KOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstract
    • SAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-of
    • KOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595
    • MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9
    Más Menos
    56 m
  • Episode 60. Emergency Podcast-AQUILA and STARGLO

    Episode 60. Emergency Podcast-AQUILA and STARGLO
    May 28 2025

    In this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and slides:


    https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025#event-materials

    Here is the youtube link for FDA proceedings:

    https://www.youtube.com/watch?v=5ecyDbK9ezc
    Más Menos
    55 m
Todavía no hay opiniones